Clincosm LogoSign in Get a demo

Ascending Dose Study of Genome Editing by Zinc Finger Nuclease Therapeutic SB-FIX in Subjects With Severe Hemophilia B

Sponsor
Sangamo Therapeutics (Industry)
Overall Status
Terminated
CT.gov ID
NCT02695160
Collaborator
(none)
1
Enrollment
1
Location
3
Arms
53.1
Actual Duration (Months)
0
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of the study is to evaluate the safety, tolerability and effect on FIX antigen and activity levels of ascending doses of SB-FIX. SB-FIX is an intravenously delivered Zinc Finger Nuclease (ZFN) Therapeutic for genome editing. It inserts a correct copy of the Factor 9 gene into the albumin locus in hepatocytes with the goal of lifelong therapeutic production of the Factor IX clotting factor.

Condition or Disease Intervention/Treatment Phase
  • Biological: SB-FIX
 Phase 1

Detailed Description

The objective of the study is to provide long term expression of Factor IX in subjects with severe hemophilia B. SB-FIX is a therapeutic for ZFN-mediated genome editing which will be delivered by adeno-associated virus (AAV)-derived vectors. SB-FIX is intended to function by placement of a corrective copy of the Factor IX transgene into the genome of the subject's own hepatocytes, under the control of the highly expressed endogenous albumin locus, and is expected to provide permanent, liver-specific expression of Factor IX for the lifetime of a hemophilia B subject.

Study Design

Study Type:
Interventional
Actual Enrollment :
1 participants
Allocation:
Non-Randomized
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase I, Open-Label, Ascending Dose Study to Assess the Safety and Tolerability of AAV2/6 Factor IX Gene Therapy Via Zinc Finger Nuclease (ZFN) Mediated Targeted Integration of SB-FIX in Adult Subjects With Severe Hemophilia B
Actual Study Start Date :
Nov 15, 2016
Actual Primary Completion Date :
Apr 19, 2021
Actual Study Completion Date :
Apr 19, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Cohort 1

SB-FIX: Low Dose

Biological: SB-FIX
Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.
Experimental: Cohort 2

SB-FIX: Medium Dose

Biological: SB-FIX
Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.
Experimental: Cohort 3

SB-FIX: High Dose

Biological: SB-FIX
Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.

Outcome Measures

Primary Outcome Measures

  1. Treatment related Adverse Events in subjects who received SB-FIX as assessed by Common Terminology Criteria for Adverse Events (CTCAE) [Up to 36 months after the SB-FIX infusion]

Secondary Outcome Measures

  1. Change from baseline in FIX antigen and activity levels [up to 36 months after the SB-FIX infusion]

  2. Change from baseline in use of Factor IX replacement therapy [Baseline and up to 36 months after the SB-FIX infusion]

    • Change from baseline in the number of FIX units infused per week

  3. Change from baseline in frequency and severity of bleeding episodes [Up to 36 months after the SB-FIX infusion]

  4. Immune response to FIX [Up to 36 months after the SB-FIX infusion]

    • Change in neutralizing antibodies to FIX from baseline over time

  5. Presence and shedding of AAV2/6 vector DNA by PCR in plasma, saliva, urine, stool and semen [Follow up until 2 consecutive measurements are negative of AAV]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Inclusion Criteria:

  • Male >18 years of age

  • Severe hemophilia B (native circulating FIX activity <1%, with or without cross reactive material)

Exclusion Criteria:

  • Presence of neutralizing antibodies

  • History of hypersensitivity response or an allergic reaction to FIX or FIX products

  • Currently receiving long acting FIX replacement therapy

  • FIX mutations known to be associated with FIX inhibitors

  • Polymorphisms in the ZFN target region

  • Presence of any liver mass on MRI, or elevated alpha-fetoprotein (AFP)

  • Any contraindication to the use of corticosteroids for immunosuppression

  • Currently receiving antiviral therapy for hepatitis B or C or with history or active hepatitis B or hepatitis C or HIV-1 or HIV1/2 antibody positive.

  • Chronic anemia, leukopenia, or thrombocytopenia

  • Past medical history of active tuberculosis or significant fungal disease

  • Symptomatic cardiovascular disease as a co-morbid condition

  • Markers of hepatic inflammation or overt or occult cirrhosis

  • History of chronic renal disease or creatinine ≥ 1.5 mg/dL

  • Systemic (iv or oral) immunomodulatory agent or steroid use (topical treatment is allowed)

  • History of chronic infection or other chronic disorder considered an unacceptable risk

  • History of malignancy except for treated basal cell or squamous cell carcinoma

  • History of alcohol or substance abuse

  • Previously received gene therapy product

  • Participation in prior investigational drug or medical device study within the previous 3 months

  • History of therapeutic non-adherence

  • Any other reason that, in the opinion of the Investigator or Medical Monitor, would render the subject unsuitable for participation in the study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Georgetown University Medical Center Washington District of Columbia United States 20007

Sponsors and Collaborators

  • Sangamo Therapeutics

Investigators

  • Study Director: Medical Monitor, Sangamo Therapeutics, Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sangamo Therapeutics
ClinicalTrials.gov Identifier:
NCT02695160
Other Study ID Numbers:
  • SB-FIX-1501
First Posted:
Mar 1, 2016
Last Update Posted:
Mar 23, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Hemophilia A
Hemophilia B

Study Results

No Results Posted as of Mar 23, 2022